The Effect of Alpha1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: a Follow Up Study
Who is this study for? Patients with defined pre-motor Parkinson's disease
What treatments are being studied? Terazosin
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The purpose of this study is to investigate the long-term effects of treatment with the selective post-synaptic a1-adrenergic blocker terazosin on serial in a population of subjects with defined pre-motor Parkinson's disease (PD) risks and abnormal imaging exams. Imaging changes will be correlated to the presence and severity of motor and non-motor symptoms of PD, measured by validated clinical scales and cardiac autonomic function tests.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Maximum Age: 85
Healthy Volunteers: f
View:
• Enrolled in the study The Effect of alpha1- adrenergic receptor antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease (STUDY #000540)
• Capacity to give informed consent
Locations
United States
California
Cedars Sinai Medical Center
RECRUITING
Los Angeles
Contact Information
Primary
Michele Gregorio, PhD
michele.gregorio@cshs.org
424-315-0021
Backup
MaryClare Kelly, MS
maryclare.kelly@cshs.org
3104238497
Time Frame
Start Date: 2022-09-23
Estimated Completion Date: 2025-11-01
Participants
Target number of participants: 15
Treatments
Experimental: terazosin therapy extension
Primary procedures in this study are MIBG scan, DAT scan, NM-MRI, and terazosin medication. Subjects will return for research visits and imaging every six months for three years. The investigators hypothesize that the rate of decline in DAT scan123I-Ioflupane uptake will be slower in subjects who have received the alpha1- adrenergic receptor antagonist terazosin, resulting in a decreased clinical conversion rate to parkinsonism.
Related Therapeutic Areas
Sponsors
Leads: Cedars-Sinai Medical Center